Get the Stockscreener App
0.664
2.71%
-0.0185
Pre-market:
.676
0.012
+1.81%
Kezar Life Sciences Inc stock is currently priced at $0.664, with a 24-hour trading volume of 298.03K.
It has seen a -2.71% decreased in the last 24 hours and a -13.28% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.6874 pivot point. If it approaches the $0.6497 support level, significant changes may occur.
Previous Close:
$0.6825
Open:
$0.685
24h Volume:
298.03K
Market Cap:
$48.34M
Revenue:
-
Net Income/Loss:
$-101.87M
P/E Ratio:
-0.5774
EPS:
-1.15
Net Cash Flow:
$-83.46M
1W Performance:
-7.70%
1M Performance:
-13.28%
6M Performance:
-20.69%
1Y Performance:
-73.65%
1D Range:
$0.655
$0.6985
52W Range:
$0.6452
$2.605
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
Kezar Life Sciences Inc Stock (KZR) Latest News
Kezar Life Sciences Inc (KZR) stock analysis: A simple moving average approach – US Post News - US Post News
US Post News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
StockTitan
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Business Wire
Ready to Jump After Recent Trade: Kezar Life Sciences Inc (KZR) – Sete News - SETE News
SETE News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
StockTitan
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Manchestertimes
Manchestertimes
Kezar Life Sciences Inc Stock (KZR) Financials Data
Kezar Life Sciences Inc (KZR) Net Income 2024
KZR net income (TTM) was -$101.87 million for the quarter ending December 31, 2023, a -49.28% decrease year-over-year.
Kezar Life Sciences Inc (KZR) Cash Flow 2024
KZR recorded a free cash flow (TTM) of -$83.45 million for the quarter ending December 31, 2023, a -38.12% decrease year-over-year.
Kezar Life Sciences Inc (KZR) Earnings per Share 2024
KZR earnings per share (TTM) was -$1.41 for the quarter ending December 31, 2023, a -39.60% decline year-over-year.
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
1.81%
1.57%
Cap:
|
Volume (24h):